

Vyzulta (latanoprostene bunod)



NEW PRODUCT SLIDESHOW

MPR

Introduction

- **Brand name:** Vyzulta
- **Generic name:** Latanoprostene bunod
- **Pharmacological class:** Prostaglandin analogue
- **Strength and Formulation:** 0.024%; ophthalmic soln; contains benzalkonium chloride
- **Manufacturer:** Valeant Pharmaceuticals
- **How supplied:** Soln—5mL
- **Legal Classification:** Rx

Vyzulta



Indications

- Open-angle glaucoma
- Ocular hypertension

Dosage & Administration

- **>16yrs:** 1 drop once daily in the PM

Considerations for Special Populations

- **Pediatric:** ≤ 16 yrs: not established
- **Pregnancy:** No human data available to establish drug-associated risk
- **Nursing mothers:** Consider mother's need and potential adverse effects on child
- **Elderly:** No overall differences in safety or effectiveness observed

Warnings/Precautions

- **Do not exceed** recommended dose (may reduce efficacy)
- History of ocular inflammation: not recommended if active inflammation
- Aphakia
- Pseudophakia with torn posterior lens capsule

Warnings/Precautions

- Risk of macular edema
- Bacterial keratitis may occur (due to multiple-dose containers)
- Contact lenses (remove; may reinsert lenses 15mins after administration)

Interactions

- Allow at least 5mins between application of other topical ophthalmic agents

Adverse Reactions

- Conjunctival hyperemia
- Eye irritation
- Eye pain
- Instillation site pain
- Increased ocular pigmentation (eg, iris [may be permanent], eyelid, eyelashes)
- Other eyelash/lid changes, macular edema (including cystoid macular edema)

Mechanism of Action

- Latanoprostene bunod is thought to lower intraocular pressure (IOP) by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes
- Reduction of IOP reduces risk of glaucomatous visual field loss

Clinical Studies

- In clinical studies up to 12 months duration, patients with open-angle glaucoma or ocular hypertension with average baseline IOPs of 26.7mmHg, the IOP-lowering effect of Vyzulta once daily was up to **7–9mmHg**

New Product Monograph

- For more information view the product monograph available at:

<https://www.empr.com/vyzulta/drug/34768/>